These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16249698)

  • 21. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.
    Meaden ER; Hoggard PG; Newton P; Tjia JF; Aldam D; Cornforth D; Lloyd J; Williams I; Back DJ; Khoo SH
    J Antimicrob Chemother; 2002 Oct; 50(4):583-8. PubMed ID: 12356805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier.
    Hayashi K; Pu H; Andras IE; Eum SY; Yamauchi A; Hennig B; Toborek M
    J Cereb Blood Flow Metab; 2006 Aug; 26(8):1052-65. PubMed ID: 16395283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin.
    Lucia MB; Rutella S; Leone G; Larocca LM; Vella S; Cauda R
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):369-78. PubMed ID: 12138343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
    Lucia MB; Rutella S; Leone G; Vella S; Cauda R
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E;
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
    Bossi P; Legrand O; Faussat AM; Legrand M; Bricaire F; Marie JP; Agut H; Diquet B; Katlama C; Huraux JM; Calvez V
    HIV Med; 2003 Jan; 4(1):67-71. PubMed ID: 12534962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection.
    Deeks SG; Hoh R; Neilands TB; Liegler T; Aweeka F; Petropoulos CJ; Grant RM; Martin JN
    J Infect Dis; 2005 Nov; 192(9):1537-44. PubMed ID: 16206068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
    Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
    J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy.
    Turriziani O; Gianotti N; Falasca F; Boni A; Vestri AR; Zoccoli A; Lazzarin A; Antonelli G
    J Med Virol; 2008 May; 80(5):766-71. PubMed ID: 18360888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
    Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
    AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses.
    Maggiolo F; Callegaro A; Gregis G; Quinzan G; Ripamonti D; Arici C; Goglio A; Suter F
    AIDS; 2002 Jan; 16(2):298-9. PubMed ID: 11807319
    [No Abstract]   [Full Text] [Related]  

  • 35. The intracellular pharmacology of antiretroviral protease inhibitors.
    Ford J; Khoo SH; Back DJ
    J Antimicrob Chemother; 2004 Dec; 54(6):982-90. PubMed ID: 15537695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.
    Cavert W; Notermans DW; Staskus K; Wietgrefe SW; Zupancic M; Gebhard K; Henry K; Zhang ZQ; Mills R; McDade H; Schuwirth CM; Goudsmit J; Danner SA; Haase AT
    Science; 1997 May; 276(5314):960-4. PubMed ID: 9139661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.
    Minuesa G; Arimany-Nardi C; Erkizia I; Cedeño S; Moltó J; Clotet B; Pastor-Anglada M; Martinez-Picado J
    J Antimicrob Chemother; 2016 Oct; 71(10):2782-92. PubMed ID: 27334660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reconstitution of thymic function in HIV-1 patients treated with highly active antiretroviral therapy.
    Ye P; Kourtis AP; Kirschner DE
    Clin Immunol; 2003 Feb; 106(2):95-105. PubMed ID: 12672400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.